Answers are grounded in this paper and cite their sources.
Narrative review evaluates liquid biopsy's role in detecting rare cancers, highlighting its clinical applications and challenges.
Liquid biopsy is a novel oncology technology with the potential to detect cancer non invasively by analysing biomarkers in bodily fluids such as blood, urine, and saliva. Liquid biopsy is an early solution to cancer detection, disease monitoring, and personalised treatment planning. Detecting circulating tumour Deoxyribonucleic Acid (DNA) (ctDNA), Circulating Tumour Cells (CTCs), and exosomes is best in detecting hard-to-reach tumours by conventional biopsies. The current review endeavours to critically evaluate the advancement and challenges of liquid biopsy in oncology and discuss implications for detecting rare and hard-to-detect cancers. The Narrative review will discuss clinical applications, technical progress, and limitations of liquid biopsy in optimising the early detection and management of patients in oncology. An extensive literature review critically evaluated current and seminal research articles on liquid biopsy, clinical trials, peer-reviewed journals, and meta-analyses. The focus was on applying liquid biopsy to detect early-stage tumours, integrate them with other diagnostic platforms, and monitor the response to treatment in rare tumours such as pancreatic cancer, neuroblastoma, and mesothelioma. Liquid biopsy has emerged as a critical technology for enhancing the accuracy of cancer and early detection, particularly for tumours otherwise difficult to biopsy. As promising as the technology is, it is plagued by limitations in the form of sensitivity, tumour heterogeneity, and low levels of tumour biomarkers during the early stage. Additionally, standardisation and regulatory approval continue to pose challenges to clinical adoption. Liquid biopsy is a technology poised to revolutionise oncology with its non invasive and reproducible potential for early detection, disease monitoring, and personalised therapy. Additional research and technological innovation are required to overcome current limitations, achieve greater clinical acceptance, and offer greater utility in detecting rare cancers.
No takes yet. Share an insight, caveat, or question.
Bansal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: